Lightnews — Scholar-powered news

Ann Mullally @mullallylab.bsky.social · 1d

Very interesting, congrats! 🎊🎉

Nuria Lopez-Bigas @nlbigas.bsky.social · 1d

🚨 New paper alert!

Sex and smoking bias in the selection of somatic mutations in human bladder

www.nature.com/articles/s41...

by @raquelbmi.bsky.social, @ferriol.bsky.social et al (in collaboration with Rosana Risques lab in @uwmedicine.bsky.social)

Sex and smoking bias in the selection of somatic mutations in human bladder - Nature

Sex bias and association with smoking history identified in the landscape of driver mutations and clonal expansions in normal human bladder tissue may explain the higher bladder cancer risk in men and smokers.

www.nature.com

3

Reposted by Ann Mullally

Justin Loke @jloke1.bsky.social · 2d

Interested in PhD in CRISPR engineering to develop new models of myeloid malignancies?!

Join me @cruk-mi.bsky.social

www.crukcentre.manchester.ac.uk/opportunitie...

For Clinically trained applicants-DM if you have queries

Deadline 17th November 2025

2 4

Ann Mullally @mullallylab.bsky.social · 8d

Pretty awesome to have Nobel Laureate, Prof. Jennifer Doudna as our Medical Grand Rounds speaker today! #CRISPR @stanforddeptmed.bsky.social

4

Reposted by Ann Mullally

Stanford Department of Medicine @stanforddeptmed.bsky.social · 16d

A @stanfordmedicine.bsky.social clinical trial, led by #StanDOM's Jason Gotlib, results in FDA approval of a new treatment for a rare, deadly blood cancer. https://stan.md/4mXxtti

1 1

Ann Mullally @mullallylab.bsky.social · 17d

Enjoyed this interview!
One of several takeaways: Constructive scientific criticism is a form of respect i.e. indicates your science matters!

Science Friday @scifri.bsky.social · 17d

Geneticist Mary-Claire King has had a remarkable career. She changed how we understand hereditary cancer, helped reunite families after Argentina’s dictatorship, and upended conventional wisdom about our evolutionary origins.

buff.ly/nwsUeYu

Photo of Dr. Mary-Claire King. Text says: “Once your evidence is good, you really have to be very
loyal to your own evidence. … You have to be very, very critical of it. But once you’re convinced you’ve got it, you can’t cave.” -Dr. Mary-Claire King

10 27

Ann Mullally @mullallylab.bsky.social · 23d

Just add students, a new academic year begins! @stanforduniversity.bsky.social

2

Reposted by Ann Mullally

Carolyn Bertozzi @carolynbertozzi.bskyverified.social · 28d

Congratulations Lucy Shapiro @stanfordmedicine.bsky.social

med.stanford.edu/news/all-new...

Scientist, advocate and entrepreneur Lucy Shapiro to receive Lasker-Koshland Special Achievement Award

Lucy Shapiro entered biology “like a bolt of lightning.” A groundbreaking scientist, mentor, drug developer and advocate for science communication is recognized for a lifetime of achievements.

med.stanford.edu

6 52

Ann Mullally @mullallylab.bsky.social · 28d

Happening today at noon! 👇🏽

Ann Mullally @mullallylab.bsky.social · Sep 3

Excited to kick off a new year of Stanford #Hematology Breakthroughs seminars! We start w/ Prof. Lucy Godley from Northwestern Feinberg SOM speaking on germline predisposition to heme malignancies, a topic on which she has immense expertise, promises to be a great seminar, next week! 👇🏽

2

Reposted by Ann Mullally

R. Coxeter @ruthcoxeter.bsky.social · Sep 7

David Baltimore, in his own words (2019).

Sixty Years of Discovery | Annual Reviews

Each of us is a story. Mine is a story of doing science for 60 years, and I am honored to be asked to tell it. Even though this autobiography was written for the Annual Review of Immunology, I have ch...

www.annualreviews.org

1 4

Reposted by Ann Mullally

Miguel Perales MD @drmiguelperales.bsky.social · Sep 7

David Baltimore, Nobel-Winning Molecular Biologist, Dies at 87 www.nytimes.com/2025/09/07/s...

David Baltimore, Nobel-Winning Molecular Biologist, Dies at 87

www.nytimes.com

2 6

Ann Mullally @mullallylab.bsky.social · Sep 3

Excited to kick off a new year of Stanford #Hematology Breakthroughs seminars! We start w/ Prof. Lucy Godley from Northwestern Feinberg SOM speaking on germline predisposition to heme malignancies, a topic on which she has immense expertise, promises to be a great seminar, next week! 👇🏽

3

Ann Mullally @mullallylab.bsky.social · Sep 2

Congrats, Steven & team - really interesting work!

1

Reposted by Ann Mullally

Steven Corsello @corsello.bsky.social · Sep 2

Excited to share our discovery of potent TRIM21 molecular glues with anticancer activity, online today @CD_AACR: "Defining the antitumor mechanism of action of a clinical-stage compound as a selective degrader of the nuclear pore complex". 1/18

3 9 27

Ann Mullally @mullallylab.bsky.social · Aug 28

Interesting, looking forward to reading this, congrats to all!

3

Reposted by Ann Mullally

Uli Steidl @steidluli.bsky.social · Aug 28

Please check out this thread on our latest paper in
@nature.com on HSC pool size regulation. rdcu.be/eCJLe
Phenomenal collaboration with @gritsmanlab.bsky.social, and driven by the outstanding Shoichiro Takeishi! @einsteincellbio.bsky.social
@einsteinmededu.bsky.social (1/6)

Haematopoietic stem cell number is not solely defined by niche availability

Nature - Haematopoietic stem cell numbers are restricted at both systemic and local levels.

rdcu.be

2 2 8

Reposted by Ann Mullally

Eric Topol @erictopol.bsky.social · Aug 14

Platelets sequester and harbor cell-free tumor DNA, which could enhance our ability to make early, microscopic diagnosis of cancer
@science.org

science.org/doi/10.1126/...
science.org/doi/10.1126/...

6 57 250

Ann Mullally @mullallylab.bsky.social · Jul 9

Rescheduled & happening today at noon! 👇🏽

Ann Mullally @mullallylab.bsky.social · May 1

Looking forward to hearing from Stanford #Hematology clinical investigator, Dr. Jason Gotlib as he recounts his outstanding work in advancing the treatment of #mastocytosis, a chronic blood cancer, using small molecule inhibitors of KIT, all the way to FDA approval!
@stanforddeptmed.bsky.social

2

Reposted by Ann Mullally

Katherine King MD PhD @thekinglab.bsky.social · Jul 2

And here it is! Our study in clonal hematopoiesis and Alzheimer’s disease — product of 5 years’ gestation. urldefense.proofpoint.com/v2/url?u=htt...

ScienceDirect.com | Science, health and medical journals, full text articles and books.

urldefense.proofpoint.com

4 8 22

Ann Mullally @mullallylab.bsky.social · Jun 23

Spectacular jacaranda in bloom on campus! @stanforduniversity.bsky.social

5

Reposted by Ann Mullally

American Society of Hematology @ash.hematology.org · Jun 20

Investing in research, education, and care is key to advancing sickle cell and blood disorders worldwide.

The ASH Foundation makes it happen.

Support the cause: https://bit.ly/4hsCh6v

🎥www.youtube.com/watc...

#WorldSickleCellDiseaseDay #Fight4Hematology #SickleCell #HemeSky

1 3

Reposted by Ann Mullally

American Society of Hematology @ash.hematology.org · Jun 19

Today is #WorldSickleCellDiseaseDay.

Sickle cell disease affects millions, but too many still face delayed diagnosis and limited access to care. Today, ASH raises awareness and invites you to be part of the progress. 🧵👇

1 4 5

Ann Mullally @mullallylab.bsky.social · Jun 18

Congrats, Ruben! Very well deserved #MPNsm

Ruben A. Mesa, MD, FACP @rubenmesamd.bsky.social · Jun 18

Honored & humbled to receive #BeutlerPrize along w/#RadekSkoda. Measuring #MPN Symptoms & developing the 4 JAKi = #TEAM of dedicated MPN Patients/Investigators/#PharmaColleagues @harrisoncn1 #SergeVerstovsek @jjkiladjian #Vannuchi @RobynScherber #JoyceNiblack @wakeforestmed

2

Ann Mullally @mullallylab.bsky.social · Jun 18

Congrats to all!

American Society of Hematology @ash.hematology.org · Jun 18

ASH is proud to recognize 11 hematologists whose groundbreaking research and leadership have transformed the understanding and care of blood disorders. Congratulations to all! 👏

🔗 https://bit.ly/3G14rIW

#HemeSky #ASHAwards

3

Reposted by Ann Mullally

Mikkael Sekeres @mikkaelsekeres.bsky.social · Jun 16

news.abbvie.com/2025-06-16-A... Wow — top line VERONA results are negative — no advantage to AZA + VEN compared to AZA alone for higher-risk #MDSsm. AZA or DAC alone remain the standard for HR-MDS. So disappointing😢 🎗️🩸

AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes

AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome...

news.abbvie.com

2 2

Reposted by Ann Mullally

Beth Psaila @bethpsaila.bsky.social · Jun 15

Exciting times for mutCALR MPNs - lovely data from the ET cohort presented in late breaking abstract at @EHA_Hematology. Rapid platelet control after just 2 doses with 89% of patients benefitting from a molecular response with INCA033989. @mpnvoice.bsky.social @mpnrf.bsky.social @mpnhv.bsky.social

4 11